FreightCar America: Long-Term Stock Growth Still On-Track
FreightCar America (RAIL) remains attractively valued despite a 19.5% revenue decline in Q2 2025, presenting potential upside as fundamentals improve. Q2 2025 saw RAIL's deliveries fall 19% to 939 railcars, mainly due to production shifts for deliveries scheduled in the second half of the year. The current revenue and delivery declines are not structural, but rather timing-related, suggesting a rebound in the latter half of 2025.
U.S. IPO Activity On Track For The Best Quarter Since Q1 2022
Q3 2025 IPO filings have reached 104 with two weeks left in the quarter, making it the strongest quarter since Q1 2022. After six large public offerings hit the tape last week, all eyes are on expected debuts from StubHub and Netskope this week. An anticipated Fed rate cut on Wednesday could fuel the fire of public debuts even more as we head into Q4 and 2026.
Mo's Smoke-Free Vision vs. Cigarette Declines: Is Transition on Track?
Altria shows cigarette volumes sliding while on! nicotine pouches surge in the second quarter, spotlighting the gradual shift toward smoke-free growth.
Gold (XAU/USD) Price Forecast: Rally Pauses, Weekly Breakout Still on Track
Gold eased Thursday, dipping toward $3,500 support after reaching $3,578 Wednesday. Despite the pullback, weekly and monthly signals confirm strong demand, keeping higher breakout targets in play.
Chipotle's Margins Slip: Can $4 Million AUV Goal Stay on Track?
CMG's margins are down in the second quarter, but efficiency upgrades and catering expansion can be a key to sustaining its $4 million AUV target.
Allarity Therapeutics shares pop as ovarian cancer therapy recieves FDA Fast Track Designation
Allarity Therapeutics (NASDAQ:ALLR) shares more than doubled after the pharmaceutical firm annoucned that its investigational therapy for advanced ovarian cancer, stenoparib, has received Fast Track Designation from the US Food and Drug Administration (FDA). The FDA's Fast Track program is designed to speed the development and review of drugs that target serious conditions and address unmet medical needs.
Biohaven: Despite Troriluzole Program Delay, FDA Review On Track For Q4 2025
Biohaven's troriluzole shows 50%-70% slowing of SCA disease progression, with FDA review now on track for Q4 2025 after a brief delay. FDA is no longer requiring an advisory committee meeting to review troriluzole to make an informed decision on whether or not it should be approved to treat SCA patients. Troriluzole's versatility across all SCA genotypes and lack of FDA-approved competing products make it a compelling investment opportunity.
Viking: Still On Track, But The Compass Needs Recalibration
Viking's oral VK2735 efficacy was strong, but tolerability issues and high discontinuation rates cloud its competitive edge in the obesity drug market. The market's perception of Viking shifted after the data, with the company now seen as a respectable contender but no longer a clear frontrunner. A buyout is more likely now, as the oral program's value is clearer; Eli Lilly and others could be interested, but Novo Nordisk likely is not.
Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track
Celldex Therapeutics, Inc.'s barzolvolimab failed to improve symptoms in eosinophilic esophagitis, but this setback doesn't impact its promising ongoing urticaria programs. Phase 3 trials for chronic spontaneous urticaria are underway, with additional studies for chronic inducible urticaria set to begin soon in 2nd half of 2025. The global urticaria market size is projected to reach $11.4 billion by 2032.
K92 Mining: Well On Track To Tier One Mid-Size Gold Producer
We reiterate our Buy rating for K92 Mining, driven by strong production growth, robust financials, and ongoing expansion at the Kainantu mine. K92's Q2 2025 results were staggering: revenue up 102%, net income up 539%, and EBITDA margin at 62%, reflecting operational excellence. The company's healthy balance sheet and ample liquidity support both mine expansion and aggressive exploration, positioning K92 for mid-tier producer status.
Will Trump's New Executive Order Fast-Track Lockheed's Space Ambitions?
Trump's executive order streamlining space regulations could accelerate Lockheed's Orion, ULA launches and broader space ambitions.
Viking Therapeutics: Still On Track
Viking Therapeutics offers a speculative opportunity, driven by its promising obesity drug pipeline and the massive potential of the GLP-1 market. Early clinical data for VK2735 is competitive, even outperforming some current leaders, though longer trials are needed for direct comparison. Risks remain high—failure in late-stage trials could mean near-total loss, but the pipeline's progress and additional MASH drug offer some risk mitigation.
